Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Must-See Attractions in Australia - 2How Deforestation Is Reshaping Mosquito-Human Contact
- 3Instructions to Pick the Right Gold Speculation Procedure: Exploring the Market
- 4Storm Goretti sweeps United Kingdom, France with winds over 120 mph
- 5One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- ByHeart sued over recalled formula by parents of infants sickened with botulism
- Astounding Treehouses All over the Planet
- Exploring ways to reduce the impact of space junk on Earth
- Do you lean your seat back on the plane? These travel pros — and real-life couple — won't do it.
- Asia's Noteworthy Destinations: A Voyager's Aide
- 'We were genuinely astonished': This moss survived 9 months outside the International Space Station and could still grow on Earth
- Merz: 80% of Syrians in Germany expected to return within three years
- NASA funds new tech for upcoming 'Super Hubble' to search for alien life: 'We intend to move with urgency'
- 10 Activities to Lift Your Consume and Bust Your Stomach
